Not All Japanese Companies Bothered By New Pharma Sales Law
This article was originally published in PharmAsia News
Executive SummaryJapan's June 1 effective date for its Pharmaceutical Affairs Law has presented a mixed bag for the drug industry, patients and a variety of new entrants into the business of selling medicines. Although the new law expanding some over-the-counter sales to convenience stores and shutting down a lot of online sales has claimed winners and losers, Daigen Pharmaceutical is experiencing a 50 percent increase in orders for its online products, such as an athlete's foot treatment. Daigen is benefiting, however, from a two-year window allowing continued online sales of drugs to people who already had been buying them before June 1. (Click here for more - a subscription may be required
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.